Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer.
Cambridge, Massachusetts--(Newsfile Corp. - June 24, 2024) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Tevard Biosciences today announced the appointment of John Maraganore, Ph.D., an industry veteran with expertise in RNA-based therapeutics, as a Strategic Advisor and Board Observer.
- Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company’s initial programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon.
- Dr. Maraganore brings a wealth of experience and knowledge in the field of RNA therapeutics. He is known for his remarkable contributions while serving as the founding CEO of Alnylam from 2002 to 2021.
Click image above to view full announcement.
About Tevard Biosciences
Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renown scientists along with life science executives and entrepreneurs who are also fathers of children with Dravet Syndrome, a rare genetic disease. Tevard is advancing the use of its novel Suppressor tRNA platform in neurological disorders, heart disease, and muscular dystrophies. The company has an ongoing research collaboration with Vertex Pharmaceuticals Incorporated aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD). For more information, please visit www.tevard.com.
Contacts:
Media
media@tevard.com
Source: Tevard
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214144
